Emerging Vaccines – Landscape & Forecast – Disease Landscape & Forecast
Vaccination programs have had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life to prevent infections and diseases associated with long-term chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, other vaccines are administered at the discretion of the prescribing physician and the patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options. This content will include coverage of current and emerging vaccines for key infectious diseases such as HPV, HZ, HBV, meningococcus, pneumococcus, seasonal influenza, RSV, and COVID-19. This content will also assess the impact of the COVID-19 pandemic on the vaccines market.
Questions answered
- What are the sizes of the populations eligible for key vaccination programs in the G7?
- Who are the key decision makers for vaccine purchasing and administration, and how does this group vary by geography?
- What are the key drivers of brand preference in a given vaccine market?
- Which pathogens are associated with the most unmet need in terms of the development of a new or improved vaccine? Which patient pools do experts anticipate will be eligible for these vaccines?
- How will the current vaccines pipeline fulfill areas of unmet need in this market?
- How will key current and emerging vaccines perform commercially?
- How has the COVID-19 pandemic impacted the use of current vaccines?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Geographies: United States, EU5, Japan
Primary research: Approximately 15 country-specific interviews with thought-leading infectious disease specialists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed events of emerging vaccines by country, segmented by key infectious diseases (HPV, HZ, meningococcus, pneumococcus, seasonal influenza, HBV, RSV, COVID-19).
Forecast: 10-year, annualized, vaccine-level sales and patient share of key vaccines through 2032, segmented by vaccines, geography, and key indications.
Emerging therapies: Registered / preregistered: 5+; Phase 3: 10+; Phase 2: 20+
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Table of contents
- Emerging Vaccines - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Forecast
- Vaccine Technologies
- Epidemiology
- Key findings
- Epidemiology populations
- Population eligible for the respiratory syncytial virus vaccine
- Population eligible for the hepatitis B virus vaccine
- Population eligible for the human papilloma virus vaccine
- Population eligible for the shingles vaccine
- Population eligible for the influenza vaccine
- Population eligible for the pneumococcal vaccine
- Population eligible for the meningococcal B vaccine
- Population eligible for the meningococcal ACWY vaccine
- Population eligible for the COVID-19 vaccine
- Number of vaccinated cases
- Key findings
- Current Treatment
- Unmet Need Overview
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Sukhvinder Singh, M.Tech., is a senior analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. He has several years of experience providing research and analytics support in the pharmaceutical domain. He has worked in numerous therapy areas, including ophthalmology, dermatology, neurology, and rare diseases. Prior to joining Clarivate, Mr. Singh was an assistant project manager on the forecasting and analytics team at DelveInsight Business Research. He was responsible for preparing epidemiology and market research reports, which included pipeline assessments, sales forecasting, and commercial opportunity assessments. He earned his master’s degree in technology and biotechnology at Amity University in Noida, India.
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University in the United Kingdom and her B.D.S. from Manipal University in India.